Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say

This article was originally published in PharmAsia News

Executive Summary

As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry

You may also be interested in...



Chinese CRO ShangPharma Opens New Facility To Support Lilly's Pipeline

China’s second-largest CRO opens new Shanghai facility to support its largest client.

ICON Goes Local As China CRO Market Heats Up

Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.

After Launching Corporate Venture Fund, WuXi Shifts Attention To China’s Domestic Market: China Earnings Roundup (Part 2)

China’s leading CRO grows revenues 24% in Q3, and establishes corporate venture fund to invest in homegrown innovation

Related Content

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel